Kulsoom Junaid, MD
Psychiatry · Saint Louis, MONPI 1497827968
Payments from drug & device makers
Across 168 payments — averaging $36.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$2K
- Avanir Pharmaceuticals, Inc.$1K
- Alkermes, Inc.$569
- Johnson & Johnson$557
- Teva Pharmaceuticals USA, Inc.$452
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$377
- plus $1K from 10 others
What the payments were for
- Travel & lodging$2,00633%
- Food & beverage$4,10267%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 27 | $2,116 |
| Avanir Pharmaceuticals, Inc. | 6 | $1,039 |
| Alkermes, Inc. | 22 | $569 |
| Johnson & Johnson(2 entities) | 22 | $557 |
| Teva Pharmaceuticals USA, Inc. | 34 | $452 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $377 |
| Acadia Pharmaceuticals Inc | 8 | $365 |
| E.r. Squibb & Sons, L.L.C. | 10 | $239 |
| Otsuka America Pharmaceutical, Inc. | 6 | $188 |
| Vanda Pharmaceuticals Inc. | 4 | $83 |
| Indivior Inc. | 4 | $67 |
| Noven Therapeutics, LLC | 2 | $30 |
| Sunovion Pharmaceuticals Inc. | 2 | $30 |
| UCB, Inc. | 1 | $18 |
| Biogen | 1 | $16 |
| Lundbeck LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$460
- NUPLAZID$246
- INGREZZA$125
- INVEGA SUSTENNA$123
- INVEGA TRINZA$123
- INVEGA$123
- SPRAVATO$123
- REXULTI$110
How this compares
$6,157 in reported general payments places this provider in the 85th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 12 | $26,025 |
| Fluoxetine DrFluoxetine Hcl | 15 | $1,658 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 14 | $1,235 |
| Fluvoxamine Maleate | 11 | $827 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 22 | $704 |
| Duloxetine Hcl | 28 | $645 |
| Quetiapine Fumarate | 32 | $571 |
| Paroxetine Hcl | 20 | $479 |
| Risperidone | 24 | $394 |
| Benztropine Mesylate | 29 | $355 |
| Escitalopram Oxalate | 16 | $273 |
| Clonazepam | 40 | $264 |
| Lamotrigine | 28 | $230 |
| Trazodone Hcl | 15 | $189 |
| Lorazepam | 49 | $150 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Saint Louis
- Junaid SyedSaint Louis$8M
- Ricky MofsenSaint Louis$4.9M
- Charles ConwaySaint Louis$3.8M
- Mohd MalikSaint Louis$2.8M
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mary KimmelSaint Louis$539K
- George GrossbergSaint Louis$521K
- Asif HabibSaint Louis$517K
- Eric LenzeSaint Louis$271K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.